



**S4 Fig.** Kaplan-Meier analyses of outcomes by treatment group: (A) overall survival and (B) progression-free survival. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; RR-CHOP, intensified the first cycle of rituximab plus eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab.